# Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

> **NCT06029673** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 69 (actual)

## Conditions studied

- Lactation Suppressed

## Interventions

- **DRUG:** Cabergoline 1 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06029673
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-07
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-07-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029673, "Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06029673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*